Defra has announced plans to form a new Animal Health and Welfare Board for England which will bring experts including farmers, veterinary surgeons, welfare experts and others from outside Government together with the Chief Veterinary Officer and civil servants to make direct policy recommendations on policy affecting the health and welfare of all kept animals such as farm animals, horses and pets.
According to Agriculture Minister Jim Paice, it is the first time that people affected by Government policy on animal health and welfare will make recommendations on those policies directly to Ministers.
Mr Paice said: "This is a completely new way of working. It replaces the old ways, where the people most affected by decisions were kept at arm's length from policy making on those subjects.
"This is about the Big Society not just existing in our communities, but in the heart of Government - helping to put the decisions in the hands of those who are doing the work on the ground.
"We've already seen the success of a partnership between farmers and the Government with the work that's been done on bluetongue - which has seen the disease virtually eradicated in this country."
Final decisions on animal health and welfare policy will remain in the hands of Government Ministers.
The Board will be made up of around 12 members, 5 senior Defra officials including the Chief Veterinary Officer, and 7-8 external members including the chair. The external members will have experience and knowledge of kept and farmed animals, animal and veterinary science, and animal welfare, and could be farmers, veterinarians, animal welfare experts.
The Board and its members will have to represent the views of all stakeholders so will be expected to communicate with them regularly.
The Board's responsibilities will include:
The Board will not be set up as a non departmental public body or arms length body. It will form part of the internal structure of Defra.
Commenting on the announcement, Harvey Locke, President of the British Veterinary Association, said: "The BVA is delighted that both the Advisory Group and Ministers have taken note of the veterinary profession's views in drawing up these plans.
"We said from the outset that genuine responsibility sharing has to be achieved before cost sharing can be discussed and we warned against earlier plans to separate animal health policy from animal welfare policy, as the two are intrinsically linked.
"Animal health and welfare policy issues require expert, scientific input and it will be essential that the new Board includes veterinary representation. We believe that the Board will provide the right mechanism for ensuring decisions are based on sound science.
"The new Board will also have to work closely with the three devolved administrations to ensure that animal health and welfare policies across the UK are joined up and complementary."
A new equine parasite supplement to the online peer-reviewed publication Parasites and Vectors has been published by Fort Dodge.
Entitled "Equine parasites: diagnosis and control - a current perspective," it contains papers on a range of topics including a major European resistance study into key anthelmintic molecules. It is authored by equine parasitology experts and opinion leaders from around the world and was first published in September 2009. It is freely available at http://www.parasitesandvectors.com/
The BEVA Trust is the Association’s philanthropic arm and in 2015 members decided that it should provide support for voluntary projects to help improve knowledge and welfare.
Since then volunteers have been rolling up their sleeves to help out with castration and welfare clinics in the UK and veterinary training schemes around the world.
Over the past 12 months a total of 42 vets and vet nurses have volunteered their time at seven BHS Education and Welfare Clinics throughout the UK.
They have helped microchip, passport, vaccinate and castrate horses recognised by Welfare Officers as needing help.
So far 598 horses and ponies have received passports and 302 been castrated.
The Trust has seen a further ten volunteers travel across the globe, working on projects in Cambodia, the Gambia, Honduras, Kiev, Nicaragua and the Ukraine.
BEVA President Vicki Nicholls said: "We thank all of the volunteers that make our Trust such a success, with special mention to Luke Edwards from the University of Liverpool and Alice Horne from Ddole Road Veterinary Clinic who have both volunteered at four clinics. We must also remember the good work of our industrious BEVA Council members and our excellent speakers at Congress this September, who are all volunteers."
For further information on BEVA Trust volunteer projects email lara@beva.org.uk to be added to the BEVA Trust mailing list.
ProteqFlu, the live attenuated canarypox equine influenza (EI) vaccine, has had its shelf life extended from 27 to 36 months.
Merial says the increased shelf life is the result of ongoing investment in vaccine research & development, and that the new data underpins the stability of modified live vaccine technology.
Merial highlights that ProteqFlu is the only equine flu vaccine in Europe to include the updated American clade 1 Ohio/03 strain in accordance with the OIE recommendations (2004).
Virbac has launched Inflacam, a meloxicam-based NSAID for the alleviation of pain in both acute and chronic musculo-skeletal disorders in dogs and horses.
Inflacam is presented both as an oral suspension and as a chewable tablet for dogs. The suspension is available in 200ml, 100ml, 42ml and 15ml sizes with a measuring syringe provided. The tablets come in two sizes - 1 mg and 2.5 mg - and are available in packs of 100. It is available for horses as an oral suspension.
Virbac Product Manager Chris Geddes MRCVS, said: "Virbac is well known for launching innovative products in areas such as dermatology and reproduction but we also aim to support practices by offering tried and trusted practice 'standards' for everyday use. Inflacam fits this brief well - meloxicam is the most commonly-used NSAID in dogs and we are delighted to add it to our range."
For more information contact your territory manager or call Virbac on 01359 243 243.
The RCVS and the Veterinary Medicines Directorate (VMD) will be holding a free Masterclass offering practical guidance on the requirements of the Veterinary Practice Premises Register, on Saturday 4 April, at BSAVA Congress.
If you are concerned about medicines inspections and would like further information about complying, this is your chance to find out what you need to do.
By 1 April, all practice premises from which medicines are supplied should be registered with the RCVS. All such premises are then subject to inspection - by either Practice Standards Scheme inspectors, if accredited under the Scheme, or VMD inspectors. Will you be ready if an inspector calls?
Suitable for veterinary surgeons, veterinary nurses and practice managers, the interactive session will be held from 10am - 12noon, with presentations from VMD and the Chief Inspector of the Practice Standards Scheme, followed by group discussion and plenty of time for questions and answers.
Attendance at the Masterclass, which will be held in Hall 6 of the ICC in Birmingham, is free to BSAVA passholders.
For your free ticket, contact Fiona Harcourt on 020 7202 0773, f.harcourt@rcvs.org.uk, or during Congress visit the RCVS Stand, number 918, opposite the catering stand in the Exhibition hall.
Endell Veterinary Group Equine Hospital in Wiltshire has stationed an equine veterinary surgeon on the Isle of Wight permanently to ensure that the island's numerous horses can receive rapid treatment when they need it.
Florus Oskam MRCVS is providing a routine and emergency mobile ambulatory service around the island 24 hours a day. Florus also has the back up of mainland ambulatory vets who also spend time on the Island. Appointments with specific vets to visit the island can also be arranged.
Florus said: "We have been providing a veterinary service on the Isle of Wight for the past 30 years and have a very loyal client base. For years they have been asking us for a permanent service on the island and we are delighted to be able to provide it at last."
Anita Niccolls, dressage rider and trainer on the Isle of Wight, added: "It's very reassuring to know that a vet of Florus's calibre is now resident on the Island and that we are able to have continuity of vet care should a horse need further treatment at the practice's equine hospital in Salisbury."
The equine events will initially take place at Rossdales Equine Hospital in Suffolk on 22nd October and at Ashbrook Veterinary Hospital in Cheshire on 5th December.
The roadshow will see a range of speakers renowned in the fields of equine veterinary medicine and QI share practical examples of improving outcomes for equine patients. Interactive workshops, real-life scenarios and case studies will show how QI techniques can be applied in practice to help teams prevent and respond to errors.
Confirmed speakers include Professor Debra Archer, Head of Equine Surgery and Professor in Equine Surgery at the University of Liverpool, Dr Alice Bird, Senior Clinical Anaesthetist at the Animal Health Trust and Dr Rachel Dean, Director of Clinical Research and Excellence in Practice, VetPartners.
President Elect of BEVA, Tim Mair, said: "There are many challenges to being an equine vet and running a successful equine practice. Even in large practices and equine hospitals, there is a risk that we operate in our own little bubble and assume that what we are doing is best practice, whereas in reality we could often do a better job.
"Clinical governance and quality improvement are tools that allow us to critically appraise our day-to-day work and identify ways in which we can continuously improve what we do – to the benefit of our patients and clients, as well as to ourselves."
The canine hip dysplasia roadshow will begin on 9th October in Gatwick, Surrey.
The event will review the condition prevalent in dogs, how best to investigate it and the available treatment options. Case examples will be used to show how the evidence can be evaluated, explain how to measure treatment outcomes and show how the use of checklists can help minimise potential errors.
It will be hosted by Mark Morton, RCVS Specialist in Small Animal Surgery (Orthopaedics). He said: "As vets we probably all undertake bits of QI on a day-to-day basis (whether we realise it or not!) but there is so much more we can do to embed it into our clinical work. Checklists, treatment guidelines and clinical auditing significantly improve our patient care and our outcomes.
"Whilst looking at hip dysplasia and the treatment options in detail, hopefully this roadshow will show how we can apply these ideas to improve our management of this condition as well as using them elsewhere.”
For the full programme of each event and to buy tickets, visit bit.ly/RCVSKnowledgeEvents.
Anyone interested in booking an RCVS Knowledge roadshow for their region can do so by contacting ebvm@rcvsknowledge.org.
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
All existing BEVA members will have their membership automatically extended until 30 June 2020. The association is also inviting vets and vet nurses who are not already BEVA members to join as online members free of charge until 30 June 2020.
BEVA President Tim Mair said: “In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD to help them through these dark times.”
BEVA membership includes:
The association is also looking at other ways to support the profession, which has included making all BEVA Congress 2019 webinars available to members via the BEVA online learning platform.
To sign up from Monday 30 March 2020 visit: https://www.beva.org.uk/Join-BEVA
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
The guidelines, which have produced by a panel of clinicians and analgesia researchers, summarise the current evidence and offer expert opinion and best practice recommendations for the use of analgesics for common scenarios.
Recommendations include:
Professor Celia Marr, Editor of the EVJ said: "The BEVA primary care clinical guidelines provide up-to-date clarity on the fundamental aspects of equine pain management for the clinician and are essential reading for all those in first opinion ambulatory roles."
The guidelines are the first in a series being produced for primary care vets by BEVA. They can be downloaded here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13198
Tim took over the role from Renate Weller at the end of BEVA Congress last week. Lucy Grieve, of Rossdales Veterinary Surgeons became President Elect.
After leaving Bristol in 1989, Tim worked in mixed practice before joining Bell Equine in 1993, becoming a partner in 1995. He led the hospital services at Bell Equine, as well as supervising the practice’s residency, intern and extern programmes, until it was bought by CVS in 2016. He continues to work as a clinician at Bell Equine whilst also working as the Equine Veterinary Director of CVS.
Tim is an RCVS Specialist in both equine internal medicine and equine soft tissue surgery and is a founding diplomate of the European College of Equine Internal Medicine; he became an Associate of the European College of Veterinary Diagnostic Imaging in 2011. He is an honorary Professor of the Royal Veterinary College and became a Fellow of the RCVS in 2016.
Editor of Equine Veterinary Education, the official journal of the British Equine Veterinary Association and the American Association of Equine Practitioners for the past 23 years, Tim has particular interests in clinical research, clinical standards and evidence based medicine, and has published widely in the professional veterinary literature, as well as authoring and editing several textbooks. He has been a member of the RCVS Practice Standards Group since 2012.
Tim has been chair of BEVA’s Education Committee since 2014, and says that during his presidential year he is keen to continue to develop BEVA’s educational activities for members at all stages of their careers.
In particular, he says he is particularly looking forward to supporting recent graduates in equine practice with relevant CPD and mentoring. He also hopes to advance the use of evidence-based veterinary medicine, and promote quality improvement in equine practice.
Tim said: "Equine practice is continuing to change and evolve with some rapidity. An important part of my focus will be on our Equine Veterinary Horizons Project, looking at anticipated advances over the next 10-15 years, what they will mean to individual practitioners and to practices and how we can adapt to and accommodate them to best advantage."
For further information visit www.beva.org.uk.
Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
According to Elanco, this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade2.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of this challenge study provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE have identified as being of concern."
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. Elanco says that experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly-based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine3.
References:
A graduate of the University of Córdoba, Spain, Sonya trained and worked across Europe and the United States, including at the Animal Health Trust, The Royal Veterinary College, Colorado State University and Nottingham University.
Her clinical interests span neurology, ophthalmology, muscular disorders, and infectious diseases, and she is widely recognised for her contributions to equine research.
She continues to contribute to ongoing studies in exercise biomarkers, toxicology, and infectious disease management, and regularly presents her findings at national and international veterinary conferences.
Andrew Jones, Clinical Director and Specialist Surgeon at CVS Endell Equine Hospital said: “Internal medicine specialists such as Dr. Gonzalez-Medina, with her comprehensive expertise spanning multiple body systems, will be instrumental in enhancing Endell’s existing services."
The new service will cover a broad spectrum of equine medical conditions, including:
Andrew added: “Our area has lacked this type of service for patients in the past, meaning horses can now access advanced internal medicine care without traveling great distances.”
The Equine Internal Medicine Service is now accepting referrals and direct cases.
https://www.endellequinehospital.co.uk.
The new tool is part of a package that also includes posters and SMS texts to support veterinary practices in raising awareness of gastric ulcers to horse owners.
Equine Gastric Ulcer Syndrome (EGUS) is a serious and common condition and any type of horse can be at risk.1 EGUS can have a profound impact on a horse’s condition and performance and can be life threatening in foals. It is a challenging condition to diagnose as the clinical signs are often vague and not always present.1
Gastroscopy is the only method currently available for a definitive diagnosis. Of the two types of disease equine squamous gastric disease is graded on a numeric scale with 1 being the least severe and 4 being the most serious. Equine glandular gastric disease can be very varied in terms of location and type so grading this disease on a score system is no longer recommended. Instead it is now usually described in terms of location, severity and appearance.2
The new tool has been designed to help vets to map the area affected by gastric disease and record the details in an accessible format. This information, together with treatment and management recommendations, can be shared easily with the client. Posters explaining gastric ulceration have been designed to help increase awareness and understanding of EGUS amongst horse owners.
Zoetis says effective treatment usually involves a combination of management and medical treatments. UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.3 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.3,4 One syringe contains enough UlcerGold for a daily dose for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
References
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
Practices which want to buy the alternative imported vaccine will need to apply to the VMD for a Special Import Certificate (SIC).
Wholesalers have agreed to stock the alternative vaccine.
Zoetis says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working hard to resume Equip Rotavirus supply as soon as possible.
For further information, contact your Zoetis account manager or ring Zoetis HQ on 0345 300 8034.
The Animal Health Trust has cut the first sod of a new cancer centre for animals in Suffolk.
The AHT's Cancer Centre will provide all three treatment options: surgery, chemotherapy and radiotherapy, on one site. The cancer facility is being purpose-built to treat horses, dogs and cats.
Sue Murphy, Head of Clinical Cancer Treatment at the AHT, said: "Having all three treatment options on one site means that whatever the diagnosis, we will be able to offer each and every patient the very best options for their specific case. With one in four dogs and one in six cats developing cancer at some time in their life this new centre will help many more animals - from Suffolk, East Anglia and all across the UK."
The new centre will also further research into cancer. Treating animals with all types of the disease will enable the AHT's vets and scientists to expand current knowledge about cancer. This will help with the development of new ways to diagnose and treat the disease.
Vets and scientists at the AHT already work collaboratively with cancer researchers looking at the disease in humans. There are a number of links between human and animal cancers which have already been identified. It is hoped that knowledge gained from the AHT Cancer Centre may also help in the understanding of cancer in people.
The AHT hopes the building will open in summer 2012 . It is launching an appeal to raise much needed funds to equip the centre with a linear accelerator. This piece of specialist equipment works by delivering high-energy radiation beams to break cancerous tumours down while sparing the surrounding normal tissue.
The AHT Cancer Centre will be one of only six veterinary facilities in the UK to house a linear accelerator.
Sue Murphy added: "Currently, there is no way to tell which animals will, and which animals won't, develop cancer. It could happen to any animal at any time. This new centre will give more animals a fighting chance of beating the disease, enabling them to lead long and healthy lives. The fact that treatments developed to benefit our pets may also lead to improvements in the prevention and treatment of cancer in humans makes this centre all the more important.
"I would urge you to donate whatever you can to help equip the centre. Your donation, however large or small, will help many more animals beat cancer and it may also help in the fight against cancer in people."
If you would like to make a donation to the AHT Cancer Centre please visit www.aht.org.uk or telephone 01638 555648.
Alternatively you can make a £5 donation by textingVETS24 £5 to 70070
The Federation of European Equine Veterinary Associations (FEEVA) and the European Federation of Farriers Associations (EFFA) have announced that they have joined forces to promote best practice in farriery.
The initiative is the result of recognition by both organisations that equine welfare is best served with the use of only properly trained farriers, working closely with veterinary surgeons as and when needed.
The organisations say that the main aims of the new partnership include:
The President of FEEVA, Professor Josh Slater said: "We look forward to working together at European level and encouraging member associations to do the same at national level, with the primary intention of enhancing equine health through first class farriery."
Pfizer Animal Health is offering the chance to win £500 worth of CPD vouchers to UK veterinary surgeons who participate in the company's 5 minute online survey about Equine Herpes Virus (EHV).
Pfizer says the intention of the survey is to find out more about veterinary perceptions and understanding of this endemic disease and its effects on the UK's valuable equine industry. There are five multi-choice questions and the survey is available online from now until 31st May 2012. Vets who show their prowess in the skills-based section of the survey will be entered to win £500 of British Equine Veterinary Association CPD vouchers.
The survey is part of Pfizer's EHV awareness campaign to help vets encourage horse owners, yard managers, trainers and breeders to keep their horses protected from the effects of this common but often under-prioritised disease. The campaign includes the provision of information leaflets and the coordination of talks to help people, who manage horses, understand the severity of EHV and the best ways to prevent it.
According to Pfizer, the prevalence of EHV can be as high as 87.5% in the UK and latent infections in horses are frequently re-activated.1,2 The consequences can be serious, with abortion outbreaks proving to be a significant economic burden to owners, trainers and breeders.3,4 However, subclinical infections, although usually regarded as less serious, can remain unrecognised and can cause suboptimal performance in horses.
Sporadic, mild respiratory disease caused by EHV can lead to interrupted training and movement restrictions.4 Even after clinical recovery from EHV-1 or upper respiratory tract infections caused by EHV-4, some horse may develop 'poor performance syndrome'.5 These can all have serious financial repercussions on the equine industry.
To take part in the survey, visit http://www.ehvaware.com/. For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients please contact your Pfizer Account Manager.
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142. 2. Allen GP. 2002. Respiratory Infections by Equine Herpesvirus Types 1 and 4. In: P. Lekeux ed. 2002. Equine Respiratory Diseases. New York: International Veterinary Information Service. 3. Garré B et al. Vet Microbiol. 2007; 122(1-2): 43-51. 4. Lunn DP et al. J Vet Intern Med. 2009; 23(3): 450-61. 5. Slater, J. 2007. Equine Herpesvirus. In: Sellon, D. and Long, M. Equine Infectious Diseases. St Louis: Saunders. 144.
A new study published in Equine Veterinary Journal's (EVJ) in partnership with the American Association of Equine Practitioners, has shown that a wireless, inertial sensor-based system can effectively measure a horse's response to a flexion test.
The authors say that opinions on the value of flexion tests in assessing equine lameness have been divided for many years, but their research should turn what has always been regarded as a subjective process into a wholly objective one.
Flexion tests are used routinely in horses with subtle or imperceptible lameness, to exacerbate the problem and make it apparent to the observer. The test involves applying a short period of pressure to the joints of the limb before re-examination, and evaluating any change in gait. However, flexion tests rely on the ability of the observer to identify and interpret changes in the horse's gait and in that respect these tests are subjective and not necessarily consistent between observers.
The research study was conducted by orthopaedic surgeons based at the University of Glasgow's School of Veterinary Medicine1. A total of 17 healthy adult horses, all in work, were fitted with sensors before being trotted in a straight line. The sensors measured vertical pelvic movement asymmetry for both right and left hind limb strides and the average difference in maximum and minimum pelvic height between right and left hind limb strides. A hind limb was randomly selected for 60 seconds of proximal flexion, after which the horse was trotted for a minimum of 10 strides. Response to the flexion was blindly assessed as negative or positive by an experienced observer.
John Marshall, lecturer in equine surgery at the University of Glasgow, who led the study, said: "A positive response to flexion resulted in significant changes to objective measurements of pelvic symmetry, supporting the use of inertial sensor systems to objectively assess response to flexion tests."
Professor Jim Moore, North American Editor of the EVJ, said: "The introduction of an objective approach to documenting lameness examination will not only help vets and trainers to investigate equine lameness more accurately. It will also serve as an unbiased method of communicating lameness examination findings among vets, trainers, farriers and other professionals."
The next phase of research will be to establish cut-off values for objective assessment of other equine lameness diagnostic procedures, such as nerve blocks.
Reference
Henry Schein said in a statement on Friday that it had sold the business in order to focus on its dental and medical markets and pursue new investment opportunities.
Covetrus says it will be using the experience, technology and global scale of the merged companies to provide veterinary practices with a more comprehensive set of integrated services and technology solutions, and tools to strengthen client relationships and grow their practice.
Covetrus launched on Nasdaq last Friday, when President and Chief Executive Officer Benjamin Shaw, said: "Today marks an important new chapter in the world of veterinary medicine, as we launch Covetrus as a new company listed on Nasdaq.
"We look forward to strengthening our customer relationships and expanding our veterinary practice partnerships worldwide as we bring more comprehensive and powerful solutions to market to meet their evolving needs and improve health and financial outcomes."